Treatment and diagnosis of melanoma
The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
1. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject
(a) an effective amount of an LXRβ agonist selected from the group consisting of:
or a pharmaceutically acceptable salt thereof;
(b) an additional therapeutic agent selected from the group consisting of an immunomodulator, a topoisomerase inhibitor, an antimetabolite, an angiogenesis inhibitor, a kinase inhibitor, an alkylating agent, and antimitotic agent.
2. The method of claim 1 , wherein the cancer is selected from the group consisting of breast cancer, colon cancer, renal cell cancer, lung cancer, hepatocellular carcinoma, gastric cancer, ovarian cancer, pancreatic cancer, esophageal cancer, prostate cancer, sarcoma, bladder cancer, melanoma and endometrial cancer.
3. The method of claim 1 , wherein the cancer is metastatic cancer.
4. The method of claim 1 , wherein the method comprises suppressing the progression or metastasis of cancer.
5. The method of claim 1 , wherein the cancer is small cell lung cancer.
6. The method of claim 1 , wherein the cancer is non-small cell lung cancer.
7. The method of claim 1 , wherein the cancer is endometrial cancer.
8. The method of claim 1 , wherein the LXRβ agonist is compound 1.
9. The method of claim 1 , wherein the LXRβ agonist is compound 2.
10. The method of claim 1 , wherein the LXRβ agonist is compound 12.
11. The method of claim 1 , wherein the LXRβ agonist is compound 25.
12. The method of claim 1 , wherein the additional therapeutic agent is selected from the group consisting of PD-1 inhibitor, a CTLA4 inhibitor, and a PDL1 inhibitor.
13. The method of claim 1 , wherein the additional therapeutic agent is the immunomodulatory selected from the group consisting of Ipilimumab, CM-10, MPDL3280A, ß-alethine, norelin, ISF-154, pentrix, pembrolizumab, abatacept, nivolumab, MAGE-A3, PEP-005, IRX-2, CTP-37, oncophage, and interferon.
14. The method of claim 1 , wherein the additional therapeutic agent is a CTLA-4 inhibitor.
15. The method of claim 1 , wherein the additional therapeutic agent is Ipilimumab.
16. The method of claim 1 , wherein the LXRβ agonist is compound 25 and the additional therapeutic agent is Ipilimumab.
17. The method of claim 1 , wherein the additional therapeutic agent is docetaxel.
18. The method of claim 1 , wherein the LXRβ agonist and the additional therapeutic agent are administered within 14 days of each other.
19. The method of claim 1 , which is prior to other anti-cancer therapy.
20. The method of claim 1 , which is subsequent to one prior anti-cancer therapy.
21. The method of claim 1 , which is subsequent to more than one prior anti-cancer therapies.
22. The method of claim 1 , wherein the cancer is resistant to a PD-1 inhibitor, a PD-L1 inhibitor, and/or a CTLA-4 inhibitor.